ºÃÎĵµ - רҵÎÄÊéд×÷·¶ÎÄ·þÎñ×ÊÁÏ·ÖÏíÍøÕ¾

ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²²¡¼ì²âµÄÒâÒå

ÓÉ ÌìÏ ·ÖÏí ʱ¼ä£º ¼ÓÈëÊÕ²Ø ÎÒҪͶ¸å µãÔÞ

ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²

²¡¼ì²âµÄÒâÒå

ÂÞÐñÙ»;²Ìµ¤

¡¾ÆÚ¿¯Ãû³Æ¡¿¡¶ºþÄÏʦ·¶´óѧѧ±¨£¨Ò½Ñ§°æ£©¡· ¡¾Äê(¾í),ÆÚ¡¿2011(008)003

¡¾ÕªÒª¡¿Ä¿µÄ:ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²²¡¼ì²â.·ÖÎö´«È¾Ô­Òò,±ÜÃâºÍÔ¤·ÀÒ½Ôº¸ÐȾºÍÒ½ÁƾÀ·×µÄ·¢Éú.·½·¨:²ÉÓÃøÁªÃâÒßÎü¸½ÊÔÑé¶Ô9001ÀýÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µÇ°»¼Õß½øÐÐÒÒÐ͸ÎÑײ¡¶¾±íÃ濹ԭ(HBsAg)¡¢Ã·¶¾ÂÝÐý¿¹Ìå(¿¹-TP)¡¢±ûÐ͸ÎÑײ¡¶¾¿¹Ìå(¿¹-HCV)¡¢ÈËÀàÃâÒßȱÏݲ¡¶¾¿¹Ô­¿¹Ìå(HIV-Ag/Ab)ËÄÏîÖ¸±êµÄ¼ì²â.½á¹û:¶Ô9001Àý»¼Õß½øÐмì²â,ÑôÐÔ»¼ÕßΪ714Àý(7.93£¥).ÆäÖÐHBsAgÑôÐÔ457Àý(5.08£¥),÷¶¾ÂÝÐýÌ忹ÌåÑôÐÔ165Àý(1.83£¥),±û¸Î¿¹ÌåÑôÐÔ86Àý(0.96£¥),°¬×̲¡¿¹Ô­¿¹Ìå³õɸÊÔÑéÑôÐÔ6Àý(0.07£¥).½áÂÛ:ͨ¹ý¶ÔÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔÖ¸±ê¼ì²â,¿ÉÃ÷È·»¼Õß½¡¿µ×´¿ö,¿ÉÒÔ¼õÉÙÒ½Ôº¸ÐȾ,¶Å¾øÒ½Ô´ÐÔ¾­Ñª´«²¥¼²²¡¶øÒýÆðµÄÒ½ÁƾÀ·×,±£»¤Ò½»¼Ë«·½µÄÀûÒæ.%Objective Before transfusion, preoperative, prenatal, hemodialysis before and endoscopic examinations were performed before infectious disease detection. Analysis of cause of infection, avoid and prevent hospital infection and medical disputes. Method: Using enzyme -linked immunosorbent assay in 9001 patients before transfusion, preoperative, prenatal, hemodialysis before and mirrors front in patients with hepatitis B virus surface antigen ( HBsAg ), Treponema pallidum antibody ( anti TP ), hepatitis C

ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²²¡¼ì²âµÄÒâÒå

ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²²¡¼ì²âµÄÒâÒåÂÞÐñÙ»;²Ìµ¤¡¾ÆÚ¿¯Ãû³Æ¡¿¡¶ºþÄÏʦ·¶´óѧѧ±¨£¨Ò½Ñ§°æ£©¡·¡¾Äê(¾í),ÆÚ¡¿2011(008)003¡¾ÕªÒª¡¿Ä¿µÄ:ÊäѪǰ¡¢ÊõÇ°¡¢²úÇ°¡¢ÑªÍ¸Ç°¼°Ç»¾µ¼ì²éÇ°½øÐиÐȾÐÔ¼²²¡¼ì²â.·ÖÎö´«È¾Ô­Òò,±ÜÃâºÍÔ¤·ÀÒ½Ôº¸ÐȾºÍÒ½ÁƾÀ·×µÄ·¢Éú.·½·¨:²ÉÓÃøÁªÃâÒßÎü¸½ÊÔÑé¶Ô9001Àý
ÍƼö¶È£º
µã»÷ÏÂÔØÎĵµÎĵµÎªdoc¸ñʽ
8wjrk3eug20088t3x4ji0cqsi0v0qh00p63
ÁìÈ¡¸£Àû

΢ÐÅɨÂëÁìÈ¡¸£Àû

΢ÐÅɨÂë·ÖÏí